Biomedical Engineering Reference
In-Depth Information
36. Xiao Y, Nieves E, Angeletti RH, Orr GA, Wolkoff AW. 2006. Rat organic anion transport-
ing protein 1A1 (Oatp1a1): purification and phosphopeptide assignment. Biochemistry
45(10):3357-3369.
37. Lee TK, Koh AS, Cui Z, Pierce RH, Ballatori N. 2003. N-Glycosylation controls func-
tional activity of Oatp1, an organic anion transporter. Am J Physiol Gastrointest Liver
Physiol 285(2):G371-G381.
38. Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C. Identifica-
tion of multiple allelic variants associated with altered transport activity among European-
and African-Americans. J Biol Chem 276(38):35669-35675.
39. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. 2006.
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and
pharmacogenetics. Gastroenterology 130(6):1793-1806.
40. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B, Stieger B,
Meier PJ, Beuers U, Kramer W, et al. 1997. Chlorambucil-taurocholate is transported
by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology
113(4):1295-1305.
41. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic
anion-transporting polypeptides mediate transport of opioid peptides across blood-brain
barrier. J Pharmacol Exp Ther 294(1):73-79.
42. Hanggi E, Grundschober AF, Leuthold S, Meier PJ, St-Pierre MV. 2006. Functional
analysis of the extracellular cysteine residues in the human organic anion transporting
polypeptide, OATP2B1. Mol Pharmacol 70(3):806-817.
43. Sugiura T, Kato Y, Tsuji A. 2006. Role of SLC xenobiotic transporters and their regulatory
mechanisms PDZ proteins in drug delivery and disposition. J Control Release 116(2):238-
246.
44. Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A. 2004. Screening of the interaction between
xenobiotic transporters and PDZ proteins. Pharm Res 21(10):1886-1894.
45. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M.
1996. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylke-
tonuria, and renal Fanconi syndrome. Cell 84(4):575-585.
46. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer
S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. 2001. Hepatocyte nuclear factor-
1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet
27(4):375-382.
47. Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD.
2006. Alterations in transporter expression in liver, kidney, and duodenum after targeted
disruption of the transcription factor HNF1alpha. Biochem Pharmacol 72(4):512-522.
48. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. 2001. Char-
acterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-
specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 276(40):37206-
37214.
49. Li N, Klaassen CD. 2004. Role of liver-enriched transcription factors in the down-
regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by
lipopolysaccharide. Mol Pharmacol 66(3):694-701.
50. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB,
Willson TM, Zavacki AM, Moore DD, Lehmann JM. 1999. Bile acids: natural ligands
for an orphan nuclear receptor. Science 284(5418):1365-1368.
Search WWH ::
Custom Search